NCT00483509 2019-10-04
NGR007
AGC Biologics S.p.A.
Phase 2 Completed
Clinical Trials
11 trialsNCT00483080 2019-01-16
Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
AGC Biologics S.p.A.
Phase 2 Completed
NCT00484276 2019-01-16
NGR010
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358084 2019-01-15
NGR019
AGC Biologics S.p.A.
Phase 2 Completed
NCT03804866 2019-01-15
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
Phase 2 Completed
NCT00484432 2018-09-27
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
AGC Biologics S.p.A.
Phase 2 Completed
NCT00994097 2018-09-27
NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358071 2018-09-27
NGR018
AGC Biologics S.p.A.
Phase 2 Completed
NCT00484341 2018-08-29
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
AGC Biologics S.p.A.
Phase 2 Completed
NCT00484211 2014-05-30
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
AGC Biologics S.p.A.
Phase 2 Completed
NCT00675012 2014-05-30
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
AGC Biologics S.p.A.
Phase 2 Completed